Story perspectives
FDA Approves Palsonify: Game-Changer for Acromegaly Treatment
9/27/2025
49 8
1 of 1
Story summary
- Crinetics Pharmaceuticals received FDA approval for Palsonify, the first once-daily acromegaly treatment, based on Phase III data.
- Palsonify showed tolerability and reduced symptom burden, with significant improvements reported by participants.
- The annual price is $290,000, higher than injectables.
- Palsonify is expected to be available in the United States in early October 2025.
- Analysts, including Morgan Stanley, raised price targets to $77.
